Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H2 2018

  • ID: 4590318
  • Drug Pipelines
  • 66 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Aduro BioTech Inc
  • Bolder Biotechnology Inc
  • Johnson & Johnson
  • Profarma
  • Savara Inc
  • Targovax ASA
  • MORE
Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Pipeline Review, H2 2018

Summary:

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Granulocyte macrophage colony stimulating factor receptor subunit alpha also known as CD116 is a receptor for granulocyte macrophage colony-stimulating factor. It is a member of the cytokine family of receptors. It plays an important role in controls the production, differentiation, and function of granulocytes and macrophages.

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) pipeline Target constitutes close to 12 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 2, 4 and 4 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Respiratory, Infectious Disease, Toxicology, Dermatology, Gastrointestinal and Hematological Disorders which include indications Melanoma, Alzheimer's Disease, Lung Disease, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Respiratory Distress Syndrome, Appendicitis, Chemotherapy Effects, Chemotherapy Induced Neutropenia, Colorectal Cancer, Crohn's Disease (Regional Enteritis), Epithelial Ovarian Cancer, Lung Infections, Lung Injury, Malignant Pleural Mesothelioma, Mild Cognitive Impairment, Multiple Myeloma (Kahler Disease), Mycobacterium Infections, Neurology, Peritonitis, Radiation Injury, Respiratory Syncytial Virus (RSV) Infections, Skin Ulcers and Wounds.

The latest report Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha - Pipeline Review, H2 2018, outlays comprehensive information on the Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The report provides a snapshot of the global therapeutic landscape for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
  • The report reviews Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) targeted therapeutics
Reasons for Purchase:
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Aduro BioTech Inc
  • Bolder Biotechnology Inc
  • Johnson & Johnson
  • Profarma
  • Savara Inc
  • Targovax ASA
  • MORE
Introduction

Report Coverage

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Overview

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Companies Involved in Therapeutics Development

Aduro BioTech Inc

Bolder Biotechnology Inc

Johnson & Johnson

Profarma

Savara Inc

Targovax ASA

XL-protein GmbH

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Drug Profiles

BBT-007 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CMJG-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GVAX Multiple Myeloma Vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GVAX Vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molgramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ONCOS-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein for RSV Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sargramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sargramostim - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine for Melanoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

XL-150 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Dormant Products

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Discontinued Products

Granulocyte Macrophage Colony Stimulating Factor Receptor Subunit Alpha (CDw116 or CD116 or CSF2RA) - Product Development Milestones

Featured News & Press Releases

Jun 06, 2018 : Partner Therapeutics (PTx) Announces US FDA Approval of Leukine (sargramostim) for the Treatment of Acute Radiation Syndrome

May 29, 2018 : Savara Provides Update on Case Reports of Inhaled Granulocyte-Macrophage Colony Stimulating Factor for the Treatment of Nontuberculous Mycobacteria Infection

May 24, 2018 : Tanner Pharma Group Signs a Distribution Agreement for Partner Therapeutics Product, Leukine

May 16, 2018 : Targovax to present at upcoming investor and industry conferences

May 02, 2018 : Targovax announces early signal of efficacy in ONCOS-102 trial in mesothelioma

Mar 29, 2018 : FDA approves Leukine for Acute Radiation Syndrome

Mar 13, 2018 : Savara Initiates Phase 2a Clinical Study of Molgradex for the Treatment of NTM Lung Infection

Feb 12, 2018 : Savara Announces IND Approval for Expansion of Molgradex Phase 3 Study Into U.S.

Feb 07, 2018 : Targovax announces completion of safety lead-in and preliminary immune activation data in ONCOS-102 trial in mesothelioma

Jan 04, 2018 : Targovax announces that ONCOS-102 generates immune activation in checkpoint inhibitor refractory melanoma patients

Dec 11, 2017: Targovax announces that first combination trials with ONCOS-102 have passed their initial, planned, independent safety reviews

Sep 12, 2017: Targovax announces start of patient recruitment in phase I/II study with ONCOS-102 in combination with durvalumab in patients with advanced peritoneal malignancies

Sep 11, 2017: Targovax: Abstract on ONCOS-102 has been presented at ESMO Conference

Aug 23, 2017: Targovax ASA: Abstract on ONCOS-102 to be presented at the ESMO 2017 Congress

May 10, 2017: Targovax recruits first patient into first ONCOS-102 /Checkpoint inhibitor melanoma study

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Indications, H2 2018

Number of Products under Development by Indications, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Investigation by Universities/Institutes, H2 2018

Products under Investigation by Universities/Institutes, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Pipeline by Aduro BioTech Inc, H2 2018

Pipeline by Bolder Biotechnology Inc, H2 2018

Pipeline by Johnson & Johnson, H2 2018

Pipeline by Profarma, H2 2018

Pipeline by Savara Inc, H2 2018

Pipeline by Targovax ASA, H2 2018

Pipeline by XL-protein GmbH, H2 2018

Dormant Products, H2 2018

Discontinued Products, H2 2018

List of Figures

Number of Products under Development by Stage of Development, H2 2018

Number of Products under Development by Therapy Areas, H2 2018

Number of Products under Development by Top 10 Indications, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Aduro BioTech Inc
  • Bolder Biotechnology Inc
  • Johnson & Johnson
  • Profarma
  • Savara Inc
  • Targovax ASA
  • XL-protein GmbH
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll